Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.

Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.

Future Oncol. 2018 Feb 09;:

Authors: Vacirca J, Caruana D, Calcanes G, Mosier M, Boccia R, McBride A

Abstract
AIM: This retrospective analysis evaluated chemotherapy-induced nausea and vomiting (CINV)-related hydration needs with palonosetron or granisetron extended-release subcutaneous (GERSC), approved in 2016 for CINV prevention.
MATERIALS & METHODS: At a community practice, CINV-related hydration per chemotherapy cycle was determined following highly (HEC) or moderately emetogenic chemotherapy (MEC) and a guideline-recommended antiemetic regimen: neurokinin 1 receptor antagonist, dexamethasone and either palonosetron only, GERSC only, or palonosetron switched to GERSC.
RESULTS: Palonosetron-only patients (n = 93) had a significantly higher mean (standard deviation) hydration rate (0.9 [1.1]) than GERSC-only patients (n = 91) (0.3 [0.6]) (p < 0.0001). Switched patients' (n = 48) hydration rates were significantly higher in the HEC subgroup with palonosetron (0.7 [1.2]) versus GERSC (0.5 [1.0]) (p = 0.028).
CONCLUSION: GERSC in a three-drug antiemetic regimen may reduce hydration needs following HEC or MEC. [Formula: see text].

PMID: 29421926 [PubMed - as supplied by publisher]

http://ift.tt/2BouFBg